Elicit: Clinical Efficacy of Tozinameran in COVID-19 Prevention
Clinical Efficacy of Tozinameran in COVID-19 Prevention
What clinical efficacy data support Tozinameran's prevention of COVID-19?
Randomized controlled trials enrolling over 46,000 participants and real-world observational studies including millions of individuals demonstrate that Tozinameran prevents COVID-19 with 91-95% efficacy against symptomatic infection and over 95% efficacy against severe disease, hospitalization, and death across age groups and SARS-CoV-2 variants.
Abstract
Tozinameran demonstrated 95% efficacy (95% CI: 90.3-97.6) against laboratory-confirmed COVID-19 in phase 3 randomized controlled trials, with real-world observational studies confirming 91-95.3% effectiveness. Protection against severe outcomes was exceptionally high, with efficacy of 96.7% against severe disease, 94.3% against hospitalization, and 96.1% against COVID-19-related death. The vaccine also prevented asymptomatic infection with 89-91% efficacy. Efficacy declined gradually from 96.2% in the first two months to 83.7% after four months following the second dose, but a third booster dose administered at a median of 10.8 months restored efficacy to 95.3%. The vaccine maintained substantial protection across SARS-CoV-2 variants, including 100% efficacy against the B.1.351 (beta) variant in South Africa, 85-97% against B.1.1.7 (alpha), and 81-96% against Delta.
Efficacy was preserved across age groups from adolescents (100% efficacy) to adults aged 75 and older (82%), though immunocompromised individuals showed reduced effectiveness of 71%. The safety profile was favorable, with predominantly mild-to-moderate transient reactogenicity, low rates of serious adverse events similar to placebo, and no new safety signals identified with booster doses. These data, derived from randomized controlled trials enrolling over 46,000 participants and real-world studies including up to 6.5 million individuals, provide robust evidence that Tozinameran prevents COVID-19 across diverse populations and variants, with particularly strong protection against severe disease, hospitalization, and death.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Screening
We screened in sources based on their abstracts that met these criteria:
- Primary Intervention: Does this study investigate Tozinameran (BNT162b2, Pfizer-BioNTech COVID-19 vaccine) as the primary intervention?
- Clinical Efficacy Outcomes: Does this study report clinical efficacy outcomes for COVID-19 prevention with laboratory-confirmed infection as the outcome measure?
- Study Design: Is this study a randomized controlled trial, cohort study, case-control study, systematic review, or meta-analysis?
- Comparative Design: Does this study compare Tozinameran to placebo, other COVID-19 vaccines, or unvaccinated controls?
- Study Population: Does this study include participants of any age group eligible for Tozinameran vaccination?
- Beyond Safety/Immunogenicity Only: Does this study report clinical efficacy outcomes (not solely immunogenicity, safety, or adverse events without efficacy data)?
- Human Clinical Research: Is this a human clinical study (not an in vitro study, animal study, preclinical research, case report, case series, editorial, commentary, or opinion piece)?
- Isolatable Tozinameran Effects: Can the effects of Tozinameran be isolated in this study (i.e., is this not a vaccine combination study where Tozinameran effects cannot be separated)?
Data extraction
We extracted various data columns from each paper including:
- Study Design: Extract study design and key methodological details.
- Study Population: Extract details about sample size, age ranges, demographics, and inclusion/exclusion criteria.
- Prevention Outcomes: Extract COVID-19 prevention outcomes measured.
- Efficacy Results: Extract quantitative efficacy/effectiveness results.
- Follow-up Duration: Extract details relevant to follow-up duration and timing of efficacy assessments.
- Variant Context: Extract information about variants and epidemiological context during the study.
- Safety Profile: Extract safety data relevant to clinical efficacy assessment.
- Subgroup Analysis: Extract efficacy results for clinically relevant subgroups.
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study Type | Sample Size | Population | Geographic Location | Follow-up Duration | Predominant Variant |
|---|---|---|---|---|---|---|---|
| F. Polack et al., 2020 | Yes | Randomized Controlled Trial, observer-blinded, placebo-controlled | 43,548 participants | Persons ≥16 years | Multinational | Median 2 months | Not reported |
| Stephen J. Thomas et al., 2021 | Yes | Randomized Controlled Trial, observer-blinded, placebo-controlled | 46,429 participants (44,165 aged ≥16 years, 2,264 aged 12-15 years) | Persons ≥12 years | Multinational | 6 months | B.1.351 (beta) in South Africa |
| E. Moreira et al., 2022 | No | Randomized Controlled Trial, placebo-controlled | 10,125 participants | Persons ≥16 years | Not specified | Median 2.5 months | Not reported |
| Eric J Haas et al., 2021 | Yes | Observational study | 6.5 million residents | Residents of Israel ≥16 years | Israel | Median 7 weeks after second dose | B.1.1.7 (94.5% prevalence) |
| G. Chodick et al., 2021 | Yes | Historical cohort study | 1,178,597 individuals | MHS members ≥16 years | Israel | 7-27 days after second dose | Not specified |
| Noa Dagan et al., 2021 | Yes | Cohort study with matched controls | 596,618 per study group | Newly vaccinated persons ≥16 years | Israel | December 2020 - February 2021 | Not reported |
| V. Hall et al., 2021 | Yes | Prospective cohort study | 23,324 participants | Healthcare workers ≥18 years | England | December 2020 - February 2021 (approximately 2 months) | B1.1.7 (dominant) |
| Megan Wallace et al., 2022 | Yes | Systematic review and meta-analysis of observational studies | 26 studies included | Persons ≥16 years, general population and sub-populations | Various countries | Studies through August 2021 | Delta variant predominant in some studies |
Efficacy Against Laboratory-Confirmed COVID-19
Primary Two-Dose Series Efficacy
| Study | Outcome | Time Point | Efficacy (95% CI) | Cases (Vaccine/Placebo) |
|---|---|---|---|---|
| F. Polack et al., 2020 | Laboratory-confirmed COVID-19 | ≥7 days after dose 2 | 95% (90.3-97.6) | 8/162 |
| Stephen J. Thomas et al., 2021 | Laboratory-confirmed COVID-19 | Through 6 months | 91.3% (89.0-93.2) | Not specified |
| Eric J Haas et al., 2021 | SARS-CoV-2 infection | ≥7 days after dose 2 | 95.3% (94.9-95.7) | Incidence: 3.1 vs 91.5 per 100,000 person-days |
| G. Chodick et al., 2021 | COVID-19 | 7-27 days after dose 2 | 94% (88-97) | Not specified |
The primary two-dose series demonstrated consistently high efficacy against laboratory-confirmed COVID-19 across both randomized controlled trials and real-world observational studies.
Temporal Trends in Efficacy
| Time Interval | Efficacy (95% CI) | Study |
|---|---|---|
| Dose 1 to dose 2 | 58.4% (40.8-71.2) | Stephen J. Thomas et al., 2021 |
| 7 days to <2 months after dose 2 | 96.2% (93.3-98.1) | Stephen J. Thomas et al., 2021 |
| 2 months to <4 months after dose 2 | 90.1% (86.6-92.9) | Stephen J. Thomas et al., 2021 |
| ≥4 months after dose 2 | 83.7% (74.7-89.9) | Stephen J. Thomas et al., 2021 |
Third (Booster) Dose Efficacy
The study by Moreira et al. evaluated a third booster dose administered a median of 10.8 months after the second dose. Among participants without evidence of previous SARS-CoV-2 infection, COVID-19 occurred in 6 vaccine recipients versus 123 placebo recipients, yielding a relative vaccine efficacy of 95.3% (95% CI: 89.5-98.3).
Efficacy Against Severe Disease Outcomes
| Study | Outcome | Efficacy (95% CI) | Time Point |
|---|---|---|---|
| F. Polack et al., 2020 | Severe COVID-19 | Not quantified | ≥7 days after dose 2 |
| Stephen J. Thomas et al., 2021 | Severe disease | 96.7% (80.3-99.9) | Through 6 months |
| Eric J Haas et al., 2021 | Severe or critical COVID-19 hospitalization | 97.5% (97.1-97.8) | ≥7 days after dose 2 |
| Noa Dagan et al., 2021 | Severe disease | 92% (75-100) | ≥7 days after dose 2 |
Efficacy Against Death
| Study | Outcome | Efficacy (95% CI) | Time Point |
|---|---|---|---|
| Eric J Haas et al., 2021 | COVID-19-related death | 96.7% (96.0-97.3) | ≥7 days after dose 2 |
| Megan Wallace et al., 2022 | Death due to COVID-19 | 96.1% (91.5-98.2) | Meta-analysis (4 studies) |
Efficacy Against Asymptomatic Infection
| Study | Outcome | Efficacy (95% CI) | Time Point |
|---|---|---|---|
| Eric J Haas et al., 2021 | Asymptomatic SARS-CoV-2 infection | 91.5% (90.7-92.2) | ≥7 days after dose 2 |
Variant-Specific Efficacy
The B.1.351 (beta) variant showed clinical protection with 100% efficacy, while the B.1.1.7 (alpha) variant demonstrated robust population effectiveness of 85-97%. The Delta variant exhibited variant-specific efficacy of 81.2% against symptomatic COVID-19.
Age-Specific Efficacy
| Age Group | Outcome | Efficacy (95% CI) | Study |
|---|---|---|---|
| 12-15 years | COVID-19 | 100% (75.3-100) | R. Frenck et al., 2021 |
| ≥75 years | Infection | 82% (61-91) | G. Chodick et al., 2021 |
Efficacy in Special Populations
The vaccine effectiveness was notably reduced in immunocompromised populations, indicating a need for enhanced vaccination strategies for these individuals. Overall vaccine effectiveness among healthcare workers was 85% after full vaccination.
Safety Profile
The safety profile of Tozinameran was favorable, with predominantly mild-to-moderate transient reactogenicity and rare serious adverse events.
Synthesis
Tozinameran demonstrates efficacy exceeding 90% against symptomatic COVID-19 in the general population, with protection above 95% against hospitalization, severe disease, and death. These benefits persist across age groups and major SARS-CoV-2 variants, with a favorable safety profile.